On Friday, Agios Pharmaceuticals Inc (NASDAQ: AGIO) opened lower -4.12% from the last session, before settling in for the closing price of $35.90. Price fluctuations for AGIO have ranged from $20.96 to $62.58 over the past 52 weeks.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
Over the past five-year period, the drop rate of yearbook sales for the company of the Healthcare sector was -2.91%. Company’s average yearly earnings per share was noted 280.76% at the time writing. With a float of $55.13 million, this company’s outstanding shares have now reached $57.02 million.
Considering the fact that the conglomerate employs 383 people, you should pay attention to its efficiency factor. In terms of profitability, gross margin is 76.16%, operating margin of -1238.1%, and the pretax margin is 2212.98%.
Agios Pharmaceuticals Inc (AGIO) Insider Activity
A key investor’s attitude towards the stock of the Biotechnology industry is another important factor to consider. The insider ownership of Agios Pharmaceuticals Inc is 3.33%, while institutional ownership is 104.75%. The most recent insider transaction that took place on Jan 06 ’25, was worth 90,233. In this transaction Chief Commercial Officer of this company sold 2,804 shares at a rate of $32.18, taking the stock ownership to the 18,906 shares. Before that another transaction happened on Jan 03 ’25, when Company’s Officer proposed sale 2,804 for $31.84, making the entire transaction worth $89,279.
Agios Pharmaceuticals Inc (AGIO) Earnings and Forecasts
Wall Street market experts anticipate that the next fiscal year will bring earnings of -1.7 per share during the current fiscal year.
According to the Wall Street analysts, stocks earnings will be around 280.76% per share during the next fiscal year.
Agios Pharmaceuticals Inc (NASDAQ: AGIO) Trading Performance Indicators
Check out the current performance indicators for Agios Pharmaceuticals Inc (AGIO). In the past quarter, the stock posted a quick ratio of 8.77. In addition, a publicly-traded company’s price to sales ratio for the trailing twelve months stands at 59.72.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is 11.37, a number that is poised to hit -1.69 in the next quarter and is forecasted to reach -6.13 in one year’s time.
Technical Analysis of Agios Pharmaceuticals Inc (AGIO)
Compared to the last year’s volume of 1.21 million, its volume of 1.33 million showed improvement in the last five days. As of the previous 9 days, the stock’s Stochastic %D was 86.61%. Additionally, its Average True Range was 2.54.
During the past 100 days, Agios Pharmaceuticals Inc’s (AGIO) raw stochastic average was set at 9.19%, which indicates a significant decrease from 34.30% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 52.78% in the past 14 days, which was lower than the 65.77% volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $46.98, while its 200-day Moving Average is $42.39. Nevertheless, the first resistance level for the watch stands at $35.45 in the near term. At $36.47, the stock is likely to face the second major resistance level. The third major resistance level sits at $37.72. If the price goes on to break the first support level at $33.18, it is likely to go to the next support level at $31.93. Should the price break the second support level, the third support level stands at $30.91.
Agios Pharmaceuticals Inc (NASDAQ: AGIO) Key Stats
There are currently 57,030K shares outstanding in the company with a market cap of 1.96 billion. Presently, the company’s annual sales total 26,820 K according to its annual income of -352,090 K. Last quarter, the company’s sales amounted to 8,960 K and its income totaled 947,920 K.
